Compare DexCom, Inc. (DXCM) vs Cloudflare Inc (NET) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Cloudflare (NET) trades at $281.69, up 4.54% with strong technical momentum as it approaches resistance near $285. The stock shows consistent earnings beats but remains unprofitable with negative net margins of -3.72%. Recent analyst upgrades highlight Cloudflare's strategic positioning in AI and cybersecurity infrastructure, though valuation metrics remain elevated with P/S of 41.06 and EV/EBITDA of 698.2.

The outlook remains cautiously optimistic given strong revenue growth trajectory and AI integration potential, but investors face significant valuation risk and ongoing profitability challenges. Analyst consensus favors bullish sentiment with 72.5% buy ratings, though current price exceeds the $261 consensus target, suggesting near-term consolidation potential.